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The present study was intended to gain additional informa-
tion on the growth regulation of prostate by somatostatin
(SRIF) and the intracellular events involved. The human pros-
tate adenocarcinoma cell lines PC-3 and LNCaP produce SRIF
and express subtypes 2 and 5 of SRIF receptors. The secretion
of SRIF is related to the proliferative status of these cells; an
inverse relationship exists between cell proliferation and the
amount of secreted SRIF. Moreover, the growth of PC-3 cells
is inhibited by SRIF overexpression and increased by block-
age of endogenous SRIF. Coincident with the increase in SRIF
secretion, the activity and levels of the SH2 domain containing
protein tyrosine phosphatase (SHP)-1, present in PC-3 cells
are augmented, but the effect can be partially prevented by
neutralization of secreted endogenously SRIF. The activity of
SHP-1 is also stimulated by the SRIF analog RC160. Overex-
pression of SHP-1 induces inhibition of PC-3 cell growth.
SHP-1 is also present in normal prostate, benign prostatic
hyperplasia, prostatic intraepithelial neoplasia, and well dif-
ferentiated adenocarcinoma. In contrast, no signal is detected
in poorly differentiated prostate cancer. These findings dem-
onstrate that SRIF inhibits PC-3 and LNCaP cell proliferation
through an autocrine/paracrine SRIF loop. This effect could
be mediated by activation of the tyrosine phosphatase SHP-1
detected in these cells as well as in human prostate and pros-
tate cancer. (J Clin Endocrinol Metab 87: 915–926, 2002)
PROSTATE CANCER IS one of the most common ma-lignancies among men in the Western world and is a
major health problem in many industrialized countries. As
the tumor is initially androgen dependent in the majority of
cases, endocrine manipulation is a first-line therapy for met-
astatic and locally advanced cancer that often achieves re-
mission or stabilization of the disease (1). However, this
period of remission is invariably followed by tumor relapse,
and the treatment options available, based on cytotoxic che-
motherapy, antiparasitic agents, or aromatase inhibitors, are
only palliative. Patients with metastatic prostate cancer de-
velop an androgen refractory phenotype that will lead to
disease progression and eventual death (2). Bearing in mind
the need to develop new therapies, it has been demonstrated
that the prostate is not exclusively dependent on androgens,
but also on additional factors of paramount importance that
maintain normal prostate function and play a role in the
development of pathological conditions. In this sense, the
importance of peptide hormones, growth factors, autocrine-
paracrine regulatory loops and stromal-epithelial interac-
tions is now widely recognized (3).
Increasing interest has developed in recent years in the role
of somatostatin (SRIF) in prostate cancer. SRIF analogs have
successfully been used to inhibit tumor growth in experi-
mental prostatic tumors in animals (4, 5); however, the re-
sults obtained in clinical trials are a subject of controversy.
Although Figg et al. (6) did not find a response in patients
with metastatic hormone refractory prostate cancer treated
with the SRIF analog somatuline, Maulard et al. (7) demon-
strated therapeutic benefit in patients with hormone refrac-
tory prostate cancer using the same analog. Conversely,
Logothetis et al. (8) observed that SMS 201–995, other SRIF
analog, stimulated prostatic tumor growth in refractory pros-
tatic carcinoma.
What is undeniable is that the peptide SRIF is a powerful
inhibitor of a wide range of biological activities, including
hormone secretion and cell proliferation (9). In this sense,
SRIF and analogs affect the growth of various normal and
tumor cells (10, 11). This effect may involve indirect mech-
anisms through the inhibition of the synthesis and secretion
of growth factors and hormones. It has been reported that
SRIF and analogs inhibit the release of pituitary GH and PRL,
and these hormones facilitate prostatic cancer growth (12).
On the other hand, both in vivo and in vitro studies provide
solid evidence for the existence of a direct antiproliferative
effect of SRIF and analogs, which is exerted through specific
SRIF receptors on normal and neoplastic cells (10). Five sub-
Abbreviations: ITS, Insulin (50 ng/ml), transferrin (50 ng/ml), and
sodium selenite (50 pg/ml); PIN, prostatic intraepithelial neoplasia;
PTP, protein tyrosine phosphatase; SHP-1, SH2 domain containing pro-
tein tyrosine phosphatase (SHP)-1; SRIF, somatostatin; sst, somatostatin
receptor.
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types of SRIF receptors (sst1–sst5) have been cloned; all struc-
turally are typical G protein-coupled receptors, and are
linked to different signal transduction pathways, including
adenylate cyclase, ion conduction channels, and tyrosine
phosphatases (9, 13, 14). There is also emerging evidence for
the hypothesis that SRIF may act as an autocrine/paracrine
regulatory factor. In fact, a variety of normal cells, endocrine
and lymphoid cells included, that synthesize endogenous
SRIF are known to express SRIF receptors (15–17). However,
it has not been documented yet whether SRIF could play a
negative autocrine role in such cells.
The presence of SRIF receptor in human prostate is evi-
dent, but contradictory results were obtained about the dis-
tribution and expression of receptor subtypes and their re-
lation to different pathological situations (18–22). No studies
have been performed to date to clarify the identity of the
receptor subtypes and mechanism(s) through which SRIF
directly affects cell proliferation. Interestingly, we recently
identified the presence of SH2 domain containing protein
tyrosine phosphatase (SHP)-1 in rat prostate (23). Other re-
cent reports suggest that SHP-1 may participate in the neg-
ative regulation of cellular proliferation by SRIF (24–26).
Therefore, a better understanding of the mechanisms under-
lying this direct inhibitory action would shed new light on
the involvement of SRIF in the etiology of prostate cancer and
could foster the development of new cancer therapies.
In this report we provide evidence that SRIF is expressed
and secreted by PC-3 and LNCaP cells, and that it regulates
prostatic cell growth through an autocrine loop. Moreover,
we identify SHP-1 in human prostatic cancer cell lines as well
as in human prostate and prostate cancer. This enzyme is
activated by SRIF in PC-3 cells, and thus it may be involved
in the antiproliferative effect of SRIF on the prostate.
Subjects and Methods
Experimental subjects
The human material selected for this study was obtained from trans-
rectal needle biopsies and routine surgical specimens of radical cystec-
tomy, transurethral resection, retropubic prostatectomy, and radical
prostatectomy. The tissues were used in the experiments after approval
by the local ethical committee. Normal adult prostate (2 cases), benign
prostatic hyperplasia (7 cases), high grade prostatic intraepithelial neo-
plasia (PIN) without coexistent adenocarcinoma (3 cases), low grade
adenocarcinoma (Gleason score 7 or less; 12 cases), high grade adeno-
carcinoma (Gleason score higher than 7; 8 cases), and large duct ade-
nocarcinoma (2 cases) were studied. Neoplasms with definite or pre-
sumptive neuroendocrine differentiation on light microscopy were not
included in the study.
Cell culture and growth assay
PC-3 and LNCaP human prostatic carcinoma cell lines were cultured
in RPMI 1640 medium (Life Technologies, Inc., Gaithersburg, MD) con-
taining 10% (PC-3) or 7% (LNCaP) FBS and antibiotics. Cell growth was
measured by cell counting using a model Cassy 1 (Scha¨rfe System,
Coulter, Hialeah, FL), after treatment of cells with 0.05% trypsin and
0.02% EDTA.
Immunoprecipitation and PTP assay
Cells were washed and solubilized with 50 mmol/liter Tris-HCl
buffer (pH 7.5) containing 140 mmol/liter NaCl, 1 mmol/liter EDTA, 0.3
mg/ml soybean trypsin inhibitor, and 0.1 mmol/liter phenylmethyl-
sulfonylfluoride (buffer A) in the presence of 1.5% 3-[(3-cholamidopro-
pyl)dimethylammonio]-1-propanesulfonate and 0.5 mmol/liter sodium
orthovanadate. The mixture was gently agitated for 30 min at 4 C and
thereafter centrifuged at 18,500 g for 20 min. Soluble proteins (400–600
g) were incubated for 2 h at 4 C with an anti-SHP-1 protein antibody
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA) prebound to Sepha-
rose-protein A (Sigma). The beads were then washed twice with buffer
A and resuspended in 180 l of 50 mmol/liter Tris-HCl (pH 7) con-
taining 0.05% bacitracin, 1 mg/ml BSA, and 5 mmol/liter dithiothreitol
for PTP assay. The reaction was initiated by the addition of 30,000 cpm
[33P]poly-(Glu,Tyr) and allowed to proceed for 10 min at 30 C as de-
scribed previously (23). PTP activity was expressed in picomoles of
inorganic phosphate released per min at 30 C from radiolabeled
substrate.
Immunoblotting
Soluble proteins (50 g) were resolved through 7.5% SDS-polyacryl-
amide gels, transferred to a nitrocellulose membrane, and immunoblot-
ted with primary antibodies. Immunoreactive proteins were visualized
by the ECL immunodetection system (Pierce Chemical Co., Rockford, IL)
with horseradish peroxidase-conjugated secondary antibodies and was
quantified by the Image Scion computer program (Scion Corp., Fred-
erick, MD).
Immunocytochemistry
Cells were grown in four-well multiwell plates on crystal slides
(25,000 cell/cm2) for immunocytochemical detection of SRIF or SHP-1.
Cells were fixed for 15 min in 0.1 mol/liter phosphate buffer (pH 7.4)
with 4% paraformaldehyde. Cell membranes were permeabilized with
0.05% Triton X-100 in PBS. The slides were blocked with 1% gelatin in
PBS and then incubated overnight with monoclonal anti-SRIF (Chemi-
con Co., Temecula, CA) or monoclonal anti-SHP-1 antibodies (Santa
Cruz Biotechnology, Inc.). SRIF was detected with biotinylated second-
ary antibody and avidin-biotin/horseradish peroxidase complex. SHP-1
was detected with antimouse IgG horseradish peroxidase-conjugated
antibodies. The color was developed with diaminobenzidene substrate.
Finally, slides were washed in PBS, dehydrated in a graded series of
ethanol, cleared in xylene, and mounted with Canada balsam. Slides
were analyzed under the microscope and photographed.
SRIF RIA
Cells were cultured for 48 h in RPMI 1640 medium supplemented
with FBS (3500 cells/cm2). After this time the medium was changed, and
cells were cultured in three experimental groups: RPMI without FBS
(0%); with insulin (50 ng/ml), transferrin (50 ng/ml), and sodium se-
lenite (50 pg/ml; ITS); or with FBS. Pooled culture media were collected
and acidified with trifluoroacetic acid and concentrated using Sep-Pak
C18 cartridges (Waters Corp., Les Ulis, France). The adsorbed peptides
were eluted with 80% acetonitrile/0.1% trifluoroacetic acid. The eluates
were evaporated under vacuum. The dried samples were analyzed for
immunoreactivity. SRIF-like immunoreactivity was measured by RIA
with rabbit polyclonal antibody (provided by Dr. E. Arilla, University
of Alcala´, Alcala´, Spain), the radioligand [125I-11Tyr]SRIF and the stan-
dard SRIF-14 as previously described (27). This assay detects SRIF-14
and molecular forms extended at the amino-terminus of SRIF-14, in-
cluding SRIF-28 and pro-SRIF.
RT-PCR
Total RNA was extracted with the Ultraspec RNA method and treated
with deoxyribonuclease I. First strand cDNA synthesis was carried out at
39 C for 2 h using Moloney murine leukemia virus (Life Technologies, Inc.).
Aliquots of the first strand reactions were used as templates for subsequent
PCR using Taq polymerase (Ecogen, Barcelona, Spain). The nucleotide
sequences of the sense and antisense primers for SRIF and the five human
SRIF receptor subtypes were: SRIF: sense, 5-TTCAGCTCAGCTTTC-
CCGGC-3; and antisense, 5-TCAATTTCTAATGCAAGGGTC-3; sst1:
sense, 5-GACACATGCTCATGCC-3; and antisense, 5-GCGTTGTC-
CATCCAGC-3; sst2: sense, 5-TGACAGTCATGAGCATCGAC-3; and
antisense, 5-GCAAAGACAGATGATGGTGA-3; sst3: sense, 5-TCATCT-
GCCTCTGCTACCTG-3; and antisense, 5-GAGCCCAAAGAAGGCAG-
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GCT-3; sst4: sense, 5-GAACCTCGTCGTGACCAGCC-3; and antisense,
5-CTGGTTGCAGGGCTTCCTGCT-3; and sst5: sense, 5-TGCAG-
GAGGGCGGTACCTG-3; and antisense, 5-TGGACGCGGCTCCGT-
GGC-3. Thermal cycling parameters were 94 C for 1 min, 30 sec of
annealing (59 C for SRIF, 63 C for sst1 and sst5, 62 C for sst2, 67 C for
sst3, and 65 C for sst4), and 72 C for 1 min with a final extension of 72
C for 10 min in a DNA thermal cycler (MJ Research, Inc., Cambridge,
MA). The number of cycles was 35 for SRIF and 25, 30, and 35 for SRIF
receptors. PCR products were separated on 2% agarose gels and visu-
alized with ethidium bromide. To confirm that PCR products resulted
from cDNA templates rather than from genomic DNA, reactions were
also carried out in the absence of reverse transcriptase during the RT
procedure.
Transfection of SHP-1 and SRIF in PC-3 cells
The human SHP-1 cDNA was subcloned into the pcDNAI neo ex-
pression vector (Invitrogen, San Diego, CA). PC-3 cells were stably
transfected using DOTAP reagent (Roche Molecular Biochemicals, In-
dianapolis, IN) with 4 g SHP-1 in pcDNAI neo vector. Stable colonies
obtained by selection with G418 (600 g/ml) were screened for the
presence of SHP-1 using Western blot analysis as described below.
Control cultures were transfected with a mock vector lacking SHP-1
cDNA.
The rat SRIF cDNA was cloned into the pUC13 expression vector (a
gift from Dr. M. Montminy, Boston, MA). PC-3 cells were seeded in
100-mm dishes or 24-well multiwell plates (for cell counting studies) and
transiently transfected using Fugene 6 reagent (Roche Molecular Bio-
chemicals) with the 1 g SRIF in pUC13 vector. Control cultures were
transfected with the same vector lacking the SRIF cDNA.
Immunohistochemistry
The material was fixed in 10% formalin for less than 24 h and em-
bedded in paraffin following routine methods. Sections (5 m thick)
were cut from the paraffin blocks and applied to positively charged
slides (Fisher Scientific, Pittsburgh, PA). Cut sections were incubated
overnight at 37 C, deparaffinized in xylene, and rehydrated through
decreasing concentrations of ethanol. The slides were then pretreated in
0.1% Difco (Detroit, MI) trypsin and microwaved in citrate buffer before
staining. Immunohistochemical staining was performed using the bi-
otin-avidin method on an automated immunostainer, and the sections
were slightly counterstained with hematoxylin. The anti-SHP1 antibody
dilution was 1:200. A histological section of every case was stained with
hematoxylin and eosin for control.
Statistical analysis
Stastitical comparisons between experimental groups were per-
formed using t test. P  0.05 was considered significant.
Results
Analysis of the SRIF and sst expression in PC-3 cells
In search of regulatory mechanisms responsible for the
control of prostatic cell proliferation, we evaluated whether
SRIF could be expressed and secreted by PC-3 cells in an
autocrine fashion. RT-PCR of PC-3 total RNA with SRIF-
specific primers resulted in a single product, 370 bp in size,
that corresponds to the expected size of an RT-PCR product
derived from prepro-SRIF mRNA (Fig. 1A). As a negative
control, the PCR was carried out with water instead of cDNA
(Fig. 1A, Cneg). To exclude the possibility that genomic DNA
was amplified, a cDNA reaction was performed without
reverse transcriptase (Fig. 1A, CDNA-free). PC-3 culture su-
pernatants were tested for SRIF immunoreactivity to deter-
mine whether PC-3 translates SRIF mRNA into peptide. Me-
dium that overlaid PC-3 cell cultures for 48 h (conditioned
medium) contained a significantly greater amount of SRIF
(103.5  18 fmol/106 cells) than control medium (levels not
detected) that had not been exposed to cells. Using antibodies
against SRIF, immunocytochemical analysis revealed the
specific expression of the peptide in PC-3 cells (Fig. 1B).
The results clearly demonstrate that SRIF is produced and
secreted by PC-3 cells, so we next determined the presence
of specific SRIF receptors. We isolated total RNA from PC-3
cells and performed RT-PCR reactions using specific pairs of
primers for sst-1, -2, -3, -4, and -5. Identical samples were
subjected to 25, 30, and 35 PCR amplification cycles to pro-
vide relative quantification of specific sstr subtype cDNAs.
The assay revealed that PC-3 cells exclusively express sst-5
and sst-2, failing to detect the expression of sst-1, sst-3, and
sst-4 (Fig. 1A).
Effects of serum depletion on SRIF secretion
To learn whether a relationship exists between cell growth
and SRIF secretion we assessed the ability of different cul-
tured conditions to alter PC-3 SRIF production. PC-3 cells
were cultured in the presence of serum for 2 d, then the
medium was removed, and the cells were cultured in serum-
free medium with or without ITS for 4 d. PC-3 cells were
counted daily during the 4 d of culture to monitor cell
growth. The results reported in Fig. 2A show that serum
deprivation increased SRIF secretion; a maximum increase of
2.5-fold over control level occurred 3 d after serum with-
drawal. This increase was prevented by the addition of ITS
(a basal medium supplement, the composition of which is
indicated in Subjects and Methods) to serum-free RPMI. In
these conditions, SRIF secretion did not vary significantly
during the 4-d culture period, and it was very similar to that
obtained on d 0. Serum withdrawal was also associated with
a dramatic reduction of PC-3 cell growth (Fig. 2B). However,
the presence of ITS increased the growth of PC-3 cells to
levels comparable to those obtained in the presence of serum.
To further support the serum deprivation-induced produc-
tion of SRIF in PC-3 cells, we next examined the expression
of prepro-SRIF mRNA by RT-PCR. As shown in Fig. 2C, the
level of prepro-SRIF transcripts was clearly up-regulated
after 24 and 72 h of PC-3 cell culture in serum-free medium.
The results obtained prompted us to analyze whether the
synthesis and secretion of SRIF could be a common factor in
other prostatic cell lines. LNCaP, an androgen-sensible hu-
man prostatic cell line, also produced and secreted SRIF,
although the level of this peptide in LNCaP was higher than
that in PC3 cells (234.6  33.5 vs. 103.5  18 fmol/106 cells).
Furthermore, we have detected sst2 and sst5 RNA in this cell
line by RT-PCR (data not shown). Serum withdrawal also
induced an increase in SRIF secreted in the culture medium,
but the kinetics of secretion were different from those in PC3
cells (Fig. 3A). A significant increase occurred since the first
day after serum withdrawal and was maximum on the third
day. The presence of ITS also produced a significant increase
in SRIF secretion, and under both conditions, serum with-
drawal and ITS treatment, the proliferation of LNCaP cells
was arrested (Fig. 3B). Serum withdrawal reduced cell pro-
liferation in PC3 cells, whereas in LNCaP it stopped cell
proliferation, maintaining a relatively constant cell number
on the days of the assays.
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Effect of SRIF on PC-3 and LNCaP cell proliferation
We then explored whether variations in the amount of
SRIF present in the culture medium could modify prostatic
cell proliferation. We first evaluated the effect of addition of
an anti-SRIF antibody to cell culture medium. As observed
in Fig. 4A, neutralization of endogenously produced SRIF
resulted in the stimulation of PC-3 cell growth of about 35%.
For LNCaP cells, a stimulation of 153  11% was observed.
Conversely, SRIF overexpression decreased the proliferation
of PC-3 cells by 45% compared with that of control cells after
transfection of PC-3 cells with SRIF expression vector (Fig.
4B). These results show that SRIF, produced by human pros-
tatic cancer cells lines and acting locally, may be involved in
the tight regulation of cell proliferation.
SRIF activates SHP-1 in PC-3 cells
Immunoblotting experiments were undertaken to exam-
ine the expression of SHP-1 in PC-3 cells and LNCaP cells
(Fig. 5). In both cases, specific monoclonal anti-SHP-1 anti-
bodies revealed a single band with an apparent molecular
mass of 66 kDa. It is clear that the expression of SHP-1 in
LNCaP was higher than that in PC-3 cells. In contrast, the
ubiquitously expressed PTPs, SHP-2 and PTP 1B, were de-
tected at similar levels in PC-3 and LNCaP cells (Fig. 5). The
expression of SHP-1 in these cell lines was confirmed by
immunocytochemical analysis (Fig. 10, C and D).
After we determined that PC-3 cells contained SHP-1, we
investigated the effects of endogenous SRIF on both its pro-
tein level and its activity. Immunoprecipitation of SHP-1
with anti-SHP-1 antibodies revealed that after 3 d of culture
without serum, SHP-1 activity was increased by 3-fold in
PC-3 cells compared with control cells cultured in the pres-
ence of serum (Fig. 6A). This increase was prevented at least
in part by addition of an anti-SRIF antibody in serum-free
medium. Furthermore, the level of SHP-1 protein was also
increased when cells were cultured in the absence of serum
FIG. 1. Expression of SRIF and sst mRNA (A) and immunocytochemical detection of SRIF in PC-3 cells (B). Cells were cultured in RMPI 1640 medium
with 10% FBS for 2 d. RT-PCR analysis of prepro-SRIF mRNA and sst1-sst5 mRNA was performed. PCR products were 370 bp for SRIF, 284 bp
for sst2, and 472 bp for sst5. CDNA-free is a control with absence of genomic DNA; Cneg is a negative control. The figure is representative of three
experiments. The positions of the DNA size molecular mass markers are shown (B). SRIF was immunostained as described in Subjects and Methods.
A typical field is shown (32; right panel). The primary antibody was omitted in a negative control (16; left panel).
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(Fig. 6B), and this increase was reduced in the presence of
anti-SRIF antibodies. Thus, serum withdrawal was associ-
ated with an increase in both SHP-1 protein level and activity,
and neutralization of endogenous SRIF reversed these ef-
fects, suggesting that serum deprivation-induced SHP-1 ac-
tivation in PC-3 cells may be due at least in part to SRIF. In
addition, when PC-3 cells were transiently transfected with
FIG. 2. Effects of serum depletion on SRIF secretion and growth of
PC-3 cells. PC-3 cells were cultured in RPMI with 10% FBS, and then
after 2 d of culture (d 0), the medium was removed, and the cells were
washed with PBS and cultured in RMPI with 10% FBS (control),
RPMI with ITS, or RPMI alone (0%) for 4 d. A, SRIF secretion was
measured by RIA in the conditioned medium. Results are expressed
as femtomoles per 106 cells (mean  SEM of five experiments per-
formed in duplicate). *, P  0.05 vs. control. B, Cell growth was
measured by cell counting, and results are expressed in 103 number
of cells. C, The level of prepro-SRIF mRNA was determined by RT-
PCR at the indicated times.
FIG. 3. Effects of serum depletion on SRIF secretion and growth of
LNCaP cells. LNCaP cells were cultured in RPMI with 7% FBS and
then after 2 d of culture (d 0), the medium was removed, and the cells
were washed with PBS and cultured in RMPI with 7% FBS (control),
RPMI with ITS, or RPMI alone (0%) for 4 d. A, SRIF secretion was
measured by RIA in the conditioned medium. Results are expressed
in femtomoles per 106 cells (mean  SEM of five experiments per-
formed in duplicate). *, P  0.05; **, P  0.01 (vs. control). B, Cell
growth was measured by cell counting, and results are expressed as
103  number of cells.
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SRIF vector, the increase in SRIF levels affected both SHP-1
activity (Fig. 7A) and SHP-1 protein level (Fig. 7B), which
were increased by 182% and 244%, respectively.
To confirm the role of SRIF in the activation of SHP-1, we
also analyzed the effect of the stable analog of SRIF, RC160,
on SHP-1 activity in PC-3 cells. Cells were incubated in the
presence of 108 mol/liter RC160 for various times, after
which they were solubilized, and SHP-1 activity was mea-
sured in SHP-1 immunoprecipitates. As shown in Fig. 8,
SHP-1 activity increased upon treatment with RC160. Stim-
ulation of SHP-1 activity was maximal after 5 min of RC160
exposure and was maintained up to 20 min. The stimulation
of SHP-1 activity by RC160 was also dose dependent. A
maximal increase was observed with 108 mol/liter RC160
(46.5% over a basal value of 100) and was maintained for
higher doses of RC160.
Stable expression of SHP-1 induced inhibition of PC-3
cell growth
To obtain direct evidence of the role of SHP-1 in the reg-
ulation of PC-3 cell proliferation, SHP-1 or empty vector was
stably expressed in PC-3 cells. Two clones expressing high
levels of SHP-1 (CSH 11 and CSH12) and one clone express-
ing empty vector (PS12) were selected (Fig. 9A). As show in
Fig. 9B, the growth of PC-3 cells overexpressing SHP-1 was
reduced compared with that of control cells and cells ex-
pressing empty vector. After 6 d of culture, the proliferation
of the two clones overexpressing SHP-1 was reduced by 35%
and 45%, respectively.
SHP-1 is present in human prostate
SHP-1 granular and cytoplasmic immunostaining was de-
tected in normal, hyperplastic, and neoplastic glands of the
prostate with different intensities and distributions (Table 1).
In normal and hyperplastic glands the immunostaining was
restricted to the luminal side of duct and acinar cells (Fig.
10A). In PIN (Fig. 10B) and well differentiated adenocarci-
noma (Fig. 10, E and F), SHP-1 antibodies also immuno-
stained the cytoplasm of neoplastic cells, but the staining was
diffuse and did not show this polar arrangement observed in
benign tissue. High grade adenocarcinomas, represented by
cases of Gleason scores 8–10, were all negative (Fig. 10, G and
H). Lymphoid cells in both prostatic specimens and controls
displayed an intense and diffuse cytoplasmic positivity.
FIG. 4. Effects of SRIF on PC-3 cell proliferation. A, PC-3 cells were
cultured in RPMI with serum and after 2 d of culture treated once
daily with goat IgG as a control or with anti-SRIF antibody for 6 d.
Then cell number was determined. Results are expressed as a per-
centage of the value obtained for the control, and values are the
mean  SEM of seven experiments performed by triplicate. ***, P 
0.001 vs. control. B, PC-3 cells were grown overnight in 24-well mul-
tiwell plates and then transfected with SRIF cDNA or empty vector
(control). Three days after transfection proliferation was evaluated by
cell counting. Results are expressed as a percentage of the control
(mean  SEM of nine separated experiments). ***, P  0.001 vs.
control.
FIG. 5. Expression of PTPs in PC-3 and LNCaP cells. Solubilized
proteins (50 g) of PC-3 and LNCaP cells were subjected to SDS-
PAGE, transferred to nitrocellulose membrane, and immunoblotted
using anti-SHP2, anti-SHP1, and anti-PTP1B antibodies. The figure
is representative of three experiments.
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Discussion
The mechanisms underlying prostate tumoral growth are
still poorly understood. Since the early work demonstrating
the presence of SRIF-like proteins in the human prostate
gland (28), a large body of evidence has indicated a prom-
inent role of SRIF in the regulation of prostate growth. How-
ever, the mechanism(s) through which SRIF directly affects
cell proliferation and the signaling pathways involved still
need to be clearly defined.
It is well known that prostatic carcinoma expresses ssts,
but conflicting data exist about the expression of subtypes
sst2 and sst5. Although sst2 was not found in primary pros-
FIG. 6. Effect of SRIF on activity and expression of SHP-1 in PC-3
cells. Cells were cultured in RPMI with 10% FBS, and after 2 d (d 0)
the medium was removed, the cells were washed and cultured in
RPMI without serum with 0.8 g/ml anti-SRIF antibody or goat IgG
as control for 3 d, then lysates were obtained. A, Equal amounts of
proteins were immunoprecipitated with anti-SHP-1 antibody, and
tyrosine phosphatase activity was measured as described in Subjects
and Methods. B, Cell lysates (50g) were subjected to SDS-PAGE and
immunoblotted with anti-SHP1 antibody. Immunoblots were ana-
lyzed densitometrically. In both cases results are expressed as a
percentage of the values obtained on d 0 (mean  SEM of three sep-
arated experiments). *, P 0.05 vs. control. #, P 0.05, cells cultured
without serum with vs. without anti-SRIF antibody.
FIG. 7. Effect of transfection-induced increment of SRIF on activity
and expression of SHP-1 in PC-3 cells. Cells were cultured in RPMI
with 10% FBS, and 24 h later cells were transfected with SRIF cDNA
or empty vector (control). Cell lysates were obtained after 3 d of
culture. A, Equivalent amounts of cell lysates were immunoprecipi-
tated with anti-SHP-1 antibody and PTP activity was measured. B,
Cell lysates (50 g) were subjected to SDS-PAGE and immunoblotted
with anti-SHP1 antibody. Immunoblots were analyzed densitometri-
cally. In both cases results are expressed as a percentage of control
(mean SEM of three separated experiments). **, P 0.01 vs. control.
Zapata et al. • SRIF Regulation of Prostate Carcinoma J Clin Endocrinol Metab, February 2002, 87(2):915–926 921
tate cancer specimens using in situ hybridization and RT-
PCR (18, 19), this subtype was revealed in metastases of
hormone refractory prostatic adenocarcinoma (20), in ortho-
topic PC-3 tumors and their metastases (21), and in Dunning
rat model R-3327 AT-1 (22). In agreement with this latter set
of reports, we detected sst2 and sst5 RNA in PC-3 cells. These
cells are derived from metastatic, rather than primary, tu-
mors. More recently, Halmos et al. (29) defined the incidence
and properties of sst in patients with organ-confined and
locally advanced prostate cancer. They found that the inci-
dence of ssts on prostate cancer did not seem to be affected
by tumor progression. SstI and sst5 mRNA were widely
distributed, whereas sst2 was rarely detected. However, fur-
ther analysis of the pattern of ssts expression is needed in a
large cohort of patients, with reference to stage and grade of
tumors, to know whether the loss or gain of an SRIF receptor
subtype may be associated with the progression of prostate
cancer.
The present study reveals that SRIF is produced by PC-3
and LNCaP cells and that this peptide is an important neg-
ative regulator of the cell proliferation of these cell lines. We
show that SRIF secretion is related to the proliferative status
of prostatic cells, as culture conditions that increase SRIF
secretion, such as serum withdrawal, induce a decrease in
PC-3 and LNCaP cell growth. Despite the opposite effect of
ITS, a basal medium supplement, on PC-3 and LNCaP cell
growth, the inverse relationship between cell proliferation
and SRIF secretion is kept. In addition, SRIF overexpression
FIG. 8. RC-160 induced stimulation of SHP-1 activity in PC-3 cells.
Cells were cultured for 24 h in RPMI with 10% FBS and in serum-free
medium overnight and incubated at 37 C for the indicated times with
108 mol/liter RC-160 (A) or for 5 min with increasing concentrations
of RC-160 (B) before solubilization and immunoprecipitation with
anti-SHP-1 antibody. Immunoprecipitates were assayed for PTP ac-
tivity. Results are the mean  SEM of three experiments made in
duplicate. *, P  0.05; **, P  0.01; ***, P  0.001 (vs. control).
FIG. 9. Effect of stable expression of SHP-1 on PC-3 cell growth.
Cloned cell lines were obtained from PC-3 cells stable transfected with
empty vector (PS12) and vector encoding SHP-1 (CSH11 and CSH12),
respectively. A, Cell lysates (50 g) were subjected to SDS-PAGE and
immunoblotted using anti-SHP1 antibody. The figure is representa-
tive of three experiments. B, PC-3 cells and clones PS12 (control),
CSH11, and CSH12 were grown in RPMI with 10% FBS. Cell growth
was daily measured by cell counting. Results are the mean  SEM of
three experiments made in triplicate. *, P  0.05; **, P  0.01; ***,
P  0.001 (vs. PS12).
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inhibits PC-3 cell growth. Conversely, blockage of endoge-
nous SRIF by specific antibodies results in an increase in PC-3
and LNCaP cell growth. Taken together, these data suggest
the existence of an autocrine/paracrine SRIF loop, inhibitory
for cell proliferation of these human prostatic cancer cell
lines. The activity of this loop could be negatively regulated,
in a cell-specific manner, by factors present in serum, as is
demonstrated by the addition of ITS to basal medium. In this
sense, Tang et al. (30) reported that in the absence of serum,
PC-3 cells show an initial phase of growth, followed by a
TABLE 1. Immunohistochemical distribution of SHP-1 in normal and pathological human prostate
Specimen SHP-1 immunostaining Location Pattern
Normal prostate (n  2)
Ducts Positive Apical cytoplasmic Granular
Glands Positive Diffuse cytoplasmic Nongranular
Hyperplastic prostate (n  7)
Hyperplastic glands Positive Apical cytoplasmic Granular
Atrophic glands Positive Diffuse cytoplasmic Nongranular
Post-atrophic glands Positive Diffuse cytoplasmic Nongranular
Basal cell hyperplasia Negative
Transitional metaplasia in ducts Intensely positive Diffuse cytoplasmic Nongranular
Inflammatory cells Intensely positive Cytoplasmic Nongranular
High grade PIN
PIN associated with cancer Positive Diffuse cytoplasmic Nongranular
PIN unassociated with cancer (n  3) Positive Diffuse cytoplasmic Nongranular
Prostate carcinoma (n  22)
Well differentiated (n  12)
Microglandular areas Positive Diffuse cytoplasmic Nongranular
Cribiform areas Weakly positive Diffuse cytoplasmic Nongranular
Poorly differentiated (n  8) Negative
Ductal adenocarcinoma (n  2) Positive Diffuse cytoplasmic Nongranular
PIN, Prostatic intraepithelial neoplasia.
FIG. 10. Distribution of SHP-1 in human prostate. Immunohistochemical demonstration of SHP-1 staining in hyperplastic glands covered by
double cell layer of benign cells, characteristic of benign prostatic hyperplasia (A). High grade PIN, displaying characteristic papilla without
stromal stalks and confined by the basal membrane, presents diffuse cytoplasmic immunostaining in atypical cells (B). C, LNCaP cells. D, PC-3
cells. Well differentiated adenocarcinoma, Gleason score 7 (3  4), composed of small glands and some solid cords of atypical cells invading the
fibromuscular stroma (E), shows diffuse cytoplasmic immunostaining for SHP-1 (F). Poorly differentiated adenocarcinoma, Gleason score 10
(5  5), composed of solid cords of atypical cells diffusely infiltrating the stroma (G), shows negative immunoreaction (H).
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phase, starting from d 3–4, in which the number of cells
begins to decrease. The initial growth phase could be due to
the autocrine production of various growth factors detected
in these cells (3). The increase in SRIF secretion (maximum
on d 3) that we observed in these cells could counterbalance
the positive growth regulatory loops and be responsible for
the decrease in cell proliferation. Instead, LNCaP cells keep
a relatively constant cell number for 5–6 d after serum with-
drawal, coincident with the increase in the SRIF level since
first day after serum withdrawal.
It is evident that the presence of SRIF in PC3 and LNCaP
epithelial cells revises classic studies in which expression of
this peptide in the prostate is limited to neuroendocrine cells
(28). However, prior studies have shown that these cell lines
consist of multipotent cells capable of both neuroendocrine
and epithelial differentiation. In fact, the treatment of cul-
tured prostate cancer cells with hormone-deficient medium
induces the acquisition of numerous neuroendocrine char-
acteristics that include the cessation of mitotic activity and
the release of some neurosecretory products into the culture
medium (31). Assuming that endogenous SRIF inhibits PC3
and LNCaP cell proliferation, the increase in its secretion
could be important for the proliferative suppression associ-
ated with the neuroendocrine differentiation event. Our
group is studying this possibility.
SHP-1, a protein tyrosine phosphatase with two N-termi-
nal Src homology 2 domains that allow binding to phospho-
tyrosines residues, plays a role in terminating growth factor
and cytokine signals by dephosphorylating critical mole-
cules (26, 32–35). SHP-1 is highly expressed in hemopoietic
cells (35); however, recent studies revealed SHP-1 is also
substantially expressed under the control of an alternative
tissue-specific promoter in a variety of nonhemopoietic cells,
especially in some malignant epithelial cells (36). However,
the precise function and targets of SHP-1 in nonhemopoietic
cells are largely unknown. In previous studies we reported
the expression of SHP-1 in rat prostate epithelial cells (23),
but the presence of this PTP in human prostate has not been
previously documented. We report now, for the first time,
that SHP-1 is also abundant in human prostatic cancer cells
lines and that its activity and protein levels are stimulated by
endogenously produced SRIF. Coincident with the increase
in SRIF secretion, the results presented here show that serum
deprivation increases the activity of SHP-1 as a result at least
in part of an increase in SHP-1 expression. This increase is
partly caused by SRIF, as it is prevented by the neutralization
of endogenously secreted SRIF. The increase in SHP-1 ac-
tivity is greater than that in SHP-1 levels, suggesting that
other factors either present in serum or induced by serum
deprivation may modulate the SHP-1 activity, although not
its level. Previously, Brevini et al. (37) demonstrated a direct
inhibitory effect of SRIF on LNCaP cell proliferation, which
could be mediated by the activation of unidentified PTP.
Numerous studies reported that SRIF can stimulate PTP
activity in other cell types, and all five SRIF receptor subtypes
have been shown to stimulate PTP in various transfected cells
(9, 13). SHP-1 has been identified as the PTP involved in the
SRIF-induced antiproliferative signal (24, 25). In fact, recent
studies have revealed that SHP-1 associates with sst2, be-
comes activated in response to SRIF, and participates in the
negative regulation of mitogenic insulin signaling (24, 26).
Other studies, however, have suggested that the more widely
expressed SHP-2 is the principal component of sst-mediated
antiproliferative signaling (38, 39). We demonstrate that
RC160 stimulates SHP-1 activity in a time- and dose-depen-
dent manner. This analog binds with high affinity to sst2 and
sst5. As we have detected both subtypes in PC-3 cells, we
cannot determine which of them is implicated in the activa-
tion of SHP-1. Recent reports show that SHP-1 associates
with sst2 and is involved in the sst2-mediated up-regulation
of p27kip1, leading to cell cycle arrest (40). Moreover, Raully
et al. (41) reported that the expression of sst2 in mouse NIH-
3T3 fibroblasts generated a negative autocrine loop by stim-
ulating SRIF production and increasing both SHP-1 activity
and SHP-1 levels. The antiproliferative effect of SRIF is also
mediated by sst5, although the mechanisms regulated by this
receptor subtype do not seem to be related to SHP-1 activa-
tion, and these results are far from conclusive. In this sense,
Cordelier et al. (42) demonstrated that the antiproliferative
signal mediated by rat sst5 implicates a cGMP-dependent
pathway, whereas Sharma et al. (43) suggest that the anti-
proliferative signaling via human sst5 leading to growth
inhibition is PTP dependent. Thus, it is necessary to deter-
mine which SRIF receptor subtype expressed is coupled to
SHP-1 in PC-3 cells. Our demonstration that SHP-1 overex-
pression reduced PC-3 cell growth is an argument in favor
of the role of SHP-1 in the negative control of cell growth.
Matozaki et al. (44) have also shown that overexpression of
SHP-1 is associated with growth inhibition and a decrease in
growth factor-induced mitogenesis. Conversely, decreased
levels of SHP-1 were associated with increased cell growth
and growth factor-mediated cell responses (35). The essential
role of SHP-1 as a negative regulator of cell growth is con-
sistent with a marked overexpansion of multiple hemopoi-
etic cell types, which has been observed in motheaten mice
characterized by mutations in the SHP-1 gene and loss of
SHP-1 activity (45). Our results clearly indicate that SHP-1 is
a component involved in the SRIF autocrine inhibitory loop,
because when you block secreted SRIF, the PC-3 cell prolif-
eration increases, decreasing the activity and the levels of
SHP-1. The overexpression of SRIF causes a decrease in PC-3
cell proliferation and an increase in the activity and levels of
SHP-1. However, this cell line expresses other PTPs, such as
SHP-2 and PTP1B, which could also mediate the antiprolif-
erative effect of SRIF in the prostate.
PC-3 is an established cell line and it may not truly rep-
resent the in vivo situation. In an attempt to determine
whether SHP-1 is expressed in human prostate we investi-
gated the expression and immunolocalization of SHP-1 in
normal, benign, and malignant prostatic tissue. We found
consistent changes in localization and intracellular distribu-
tion of SHP-1, associated with the transition from benign
prostate to prostate cancer and also with a variable degree of
differentiation within malignant tissue. SHP-1 expression is
detected in normal prostate, benign prostatic hyperplasia,
high grade PIN, and well differentiated adenocarcinoma. In
contrast, no signal is detected in poorly differentiated pros-
tate cancer. This correlated well with our findings that the
expression level of SHP-1 is higher in LNCaP than in PC-3
cells. LNCaP is a well differentiated human prostatic cancer
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cell line. However, PC-3 is a highly invasive, androgen-
independent, and less differentiated human prostatic cancer
cell line (46). Moreover, the tumors formed by both cell lines
after injections in athymic mice are different (47, 48). Tumors
formed by PC-3 cells are undifferentiated adenocarcinomas,
whereas LNCaP tumors are better differentiated. Thus, the
loss of SHP-1 expression may play an important role during
the development and progression of prostate cancer. In this
sense, SHP-1 can be activated by SRIF and participate in the
negative regulation of growth factor signaling. A low ex-
pression of SHP-1 has been detected in Burkitt lymphoma
(49) and in erythroid progenitors of patients with polycy-
themia vera, which are hypersensitive to the mitogenic ef-
fects of growth factors and cytokines (50). Growth factors and
their receptors seem to play an important role in the control
of prostate growth. Recent studies have provided evidence
that there is a shift toward increased expression and auto-
crine production of growth factors during the progression of
prostate cancer, which represents an adaptation in response
to androgen ablation (3). The androgen deprivation could
also lead to the development of a negative growth-regulating
loop involving SRIF. However, this loop could be deficient
due to low expression of SHP-1. Assuming that the incidence
of ssts on prostate cancer appears to be unaffected by tumor
progression (29), postreceptor signaling defects, such as loss
of SHP-1, may play a role in the pathogenesis of prostate
cancer by permitting the persistence of signals generated by
growth factors. In this sense, Douziech et al. (51) demon-
strated that SRIF exerts different effects on human pancreatic
cancer cell growth depending upon the presence or absence
of SHP-1. The antiproliferative effect of the peptide is not
observed when the enzyme is not expressed.
Despite the attention focused in recent years on the effi-
cacy of SRIF to treat prostate cancer, the molecular mecha-
nisms used by this peptide are far from being well docu-
mented. We have demonstrated that PC-3 and LNCaP cells
synthesize and secrete SRIF, and this peptide, acting through
sst2 and/or sst5, inhibits cell proliferation. This antiprolif-
erative effect could be mediated by SHP-1, a PTP present in
prostatic cells and regulated, both short and long term, by
endogenously secreted SRIF. We have identified SHP-1 in
normal human prostate, benign prostatic hyperplasia, and
well differentiated prostate cancer, but it seems to be lacking
in poorly differentiated advanced prostate cancer. SHP-1 can
play a key role in the control of prostatic cell proliferation,
and its cellular presence may determine the therapeutic po-
tential of SRIF in the control of prostate cancer. Future studies
are necessary to determine whether the loss of this negative
regulation contributes to prostatic tumor development and
progression.
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